7MZL

SARS-CoV-2 receptor binding domain bound to Fab PDI 210

7MZL の概要

• エントリーDOI: 10.2210/pdb7mzl/pdb
• 関連するPDBエントリー: 7MZF 7MZG 7MZH 7MZI 7MZJ 7MZK
• 分子名称: Spike protein S1, PDI 210 heavy chain, PDI 210 light chain, ... (4 entities in total)
• 機能のキーワード: sars-cov-2, spike, rbd, human antibody, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 71095.54

構造登録者

Pymm, P.,Chan, L.J.,Dietrich, M.H.,Tan, L.L.,Tham, W.H. (登録日: 2021-05-24, 公開日: 2021-10-06, 最終更新日: 2023-10-18)

主引用文献

Wheatley, A.K.,Pymm, P.,Esterbauer, R.,Dietrich, M.H.,Lee, W.S.,Drew, D.,Kelly, H.G.,Chan, L.J.,Mordant, F.L.,Black, K.A.,Adair, A.,Tan, H.X.,Juno, J.A.,Wragg, K.M.,Amarasena, T.,Lopez, E.,Selva, K.J.,Haycroft, E.R.,Cooney, J.P.,Venugopal, H.,Tan, L.L.,O Neill, M.T.,Allison, C.C.,Cromer, D.,Davenport, M.P.,Bowen, R.A.,Chung, A.W.,Pellegrini, M.,Liddament, M.T.,Glukhova, A.,Subbarao, K.,Kent, S.J.,Tham, W.H.
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Cell Rep, 37:109822-109822, 2021

PubMed Abstract: Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.

PubMed: 34610292
DOI: 10.1016/j.celrep.2021.109822

実験手法

X-RAY DIFFRACTION (3.7 Å)